# A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07284758/  
OnCo record `nct07284758` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Dexamethasone in multiple myeloma, run by C4 Therapeutics, Inc., now recruiting.

## Summary

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07284758 by C4 Therapeutics, Inc., with 100 participants planned, started 2026-02-18 and due to reach its primary completion in 2030-03. Interventions recorded: Cemsidomide, Dexamethasone. Conditions listed: Multiple Myeloma, Relapsed/Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07284758
- Phase: 2
- Setting: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
- Sponsor: C4 Therapeutics, Inc.
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT07284758: https://clinicaltrials.gov/study/NCT07284758

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/)
- companies: [C4 Therapeutics](https://onco.cc/companies/c4-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07284758.json